Volume 73, Issue 7, Pages 856-862 (April 2008) A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients N.C.T. Kong, J. Beran, S.A. Kee, J.L. Miguel, C. Sánchez, J.-M. Bayas, A. Vilella, F. Calbo-Torrecillas, E. López de Novales, K. Srinivasa, M. Stoffel, B. Hoet Kidney International Volume 73, Issue 7, Pages 856-862 (April 2008) DOI: 10.1038/sj.ki.5002725 Copyright © 2008 International Society of Nephrology Terms and Conditions
Figure 1 Disposition of patients. Kidney International 2008 73, 856-862DOI: (10.1038/sj.ki.5002725) Copyright © 2008 International Society of Nephrology Terms and Conditions
Figure 2 Persistence of anti-HBs seroprotection rates. Fisher exact test two-sided P<0.05 at all time points except months 7 and 12, which are included for comparison. Kidney International 2008 73, 856-862DOI: (10.1038/sj.ki.5002725) Copyright © 2008 International Society of Nephrology Terms and Conditions
Figure 3 Percentage of vaccine recipients with anti-HBs ≥100 mIU ml−1 over the long-term follow-up. Fisher exact test two-sided P>0.05 for all time points except months 7 and 12 only, which are included for comparison. Kidney International 2008 73, 856-862DOI: (10.1038/sj.ki.5002725) Copyright © 2008 International Society of Nephrology Terms and Conditions
Figure 4 Pre- and post-month 42 booster geometric mean anti-HBs titers. Kidney International 2008 73, 856-862DOI: (10.1038/sj.ki.5002725) Copyright © 2008 International Society of Nephrology Terms and Conditions